Disulfiram - Ora Bio

Drug Profile

Disulfiram - Ora Bio

Alternative Names: ORA-101; ORA-102

Latest Information Update: 06 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Ora Bio
  • Class Antineoplastics; Eye disorder therapies; Small molecules
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Age-related macular degeneration; Non-small cell lung cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Aug 2015 No recent reports of development identified - Phase-II for Age-related macular degeneration (Combination therapy) in Israel (PO)
  • 06 Aug 2015 No recent reports of development identified - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy) in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top